UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.025

Sortiert nach

Cystic fibrosis

The Lancet (British edition), 2021-06, Vol.397 (10290), p.2195-2211

2021

Link zum Volltext

Verfügbarkeit prüfen

Opening the “Can of Worms”: Preparing Teachers to Address Issues Relating to “Race”

Frontiers in education (Lausanne), 2021-01, Vol.5

Davies, Jane

2021

Link zum Volltext

Verfügbarkeit prüfen

The life rafts sailed; Now let's take stock and set the course ahead (Commentary)

Journal of cystic fibrosis, 2021-12, Vol.20, p.29-30

Davies, Jane C

2021

Link zum Volltext

Verfügbarkeit prüfen

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

The New England journal of medicine, 2017-11, Vol.377 (21), p.2024-2035

2017

Link zum Volltext

Verfügbarkeit prüfen

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

The New England journal of medicine, 2015-07, Vol.373 (3), p.220-231

2015

Link zum Volltext

Verfügbarkeit prüfen

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR

American journal of respiratory and critical care medicine, 2018-01, Vol.197 (2), p.214-224

2018

Link zum Volltext

Verfügbarkeit prüfen

Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane

eLife, 2021-04, Vol.10

2021

Link zum Volltext

Verfügbarkeit prüfen

Future therapies for cystic fibrosis

Nature communications, 2023-02, Vol.14 (1), p.693-693, Article 693

2023

Link zum Volltext

Verfügbarkeit prüfen

Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway

PloS one, 2021-02, Vol.16 (2), p.e0246050-e0246050

2021

Link zum Volltext

Verfügbarkeit prüfen

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

American journal of respiratory and critical care medicine, 2021-03, Vol.203 (5), p.585-593

2021

Link zum Volltext

Verfügbarkeit prüfen

Outdoor air pollution and cystic fibrosis

Paediatric respiratory reviews, 2018-09, Vol.28, p.80-86

2018

Link zum Volltext

Verfügbarkeit prüfen

The Th17 Pathway in Cystic Fibrosis Lung Disease

American journal of respiratory and critical care medicine, 2011-07, Vol.184 (2), p.252-258

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

The lancet respiratory medicine, 2016-02, Vol.4 (2), p.107-115

2016

Link zum Volltext

Verfügbarkeit prüfen

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The New England journal of medicine, 2018-10, Vol.379 (17), p.1599-1611

2018

Link zum Volltext

Verfügbarkeit prüfen

Visualising early lung disease in CF: the emergence of MRI

Thorax, 2017-08, Vol.72 (8), p.682

Davies, Jane C

2017

Link zum Volltext

Verfügbarkeit prüfen

Horses for courses: Learning from functional tests of pulmonary health?

Pediatric pulmonology, 2020-08, Vol.55 (8), p.1855-1858

2020

Link zum Volltext

Verfügbarkeit prüfen

Monitoring early stage lung disease in cystic fibrosis

Current opinion in pulmonary medicine, 2020-11, Vol.26 (6), p.671

2020

Link zum Volltext

Verfügbarkeit prüfen

Supply Chain Integration, Product Modularity, and Market Valuation: Evidence from the Solar Energy Industry

Production and operations management, 2013-11, Vol.22 (6), p.1494-1508

2013

Link zum Volltext

Verfügbarkeit prüfen

COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No

Chest, 2022-01, Vol.161 (1), p.21-24

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the upper and lower airway microbiota in children with chronic lung diseases

PloS one, 2018-08, Vol.13 (8), p.e0201156-e0201156

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

American journal of respiratory and critical care medicine, 2013-06, Vol.187 (11), p.1219-1225

2013

Link zum Volltext

Verfügbarkeit prüfen

Rebuttal From Dr Thursfield et al

Chest, 2022-01, Vol.161 (1), p.25-25

2022

Link zum Volltext

Verfügbarkeit prüfen

Pseudomonas aeruginosa in the Cystic Fibrosis Airway: Does It Deserve Its Reputation as a Predatory "Bully"?

American journal of respiratory and critical care medicine, 2021-04, Vol.203 (8), p.1027-1030

2021

Link zum Volltext

Verfügbarkeit prüfen

Where are we with transformational therapies for patients with cystic fibrosis?

Current opinion in pharmacology, 2017-06, Vol.34, p.70-75

2017

Link zum Volltext

Verfügbarkeit prüfen

The future of CFTR modulating therapies for cystic fibrosis

Current opinion in pulmonary medicine, 2015-11, Vol.21 (6), p.579-584

Davies, Jane C

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.025

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.611)
Mit Volltextzugriff
(1.679)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Cystic fibrosis

Opening the “Can of Worms”: Preparing Teachers to Address Issues Relating to “Race”

The life rafts sailed; Now let's take stock and set the course ahead (Commentary)

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR

Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane

Future therapies for cystic fibrosis

Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

Outdoor air pollution and cystic fibrosis

The Th17 Pathway in Cystic Fibrosis Lung Disease

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Visualising early lung disease in CF: the emergence of MRI

Horses for courses: Learning from functional tests of pulmonary health?

Monitoring early stage lung disease in cystic fibrosis

Supply Chain Integration, Product Modularity, and Market Valuation: Evidence from the Solar Energy Industry

COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No

Comparison of the upper and lower airway microbiota in children with chronic lung diseases

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

Rebuttal From Dr Thursfield et al

Pseudomonas aeruginosa in the Cystic Fibrosis Airway: Does It Deserve Its Reputation as a Predatory "Bully"?

Where are we with transformational therapies for patients with cystic fibrosis?

The future of CFTR modulating therapies for cystic fibrosis

Suchergebnisse filtern